



RJ GROUP
Aiming New Heights

RJ Biotech Ltd.

15/11/2022

BSE Ltd.

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai- 400001

Ref: Scrip Code: 511736

Sub: Submission of un-audited Financial Results for the quarter ended September 30th, 2022


Pursuant to appointment of the Interim Resolution Professional ('IRP') by the Hon'ble National Company Law Tribunal (NCLT), Mumbai, and in accordance with the provisions of the Insolvency and Bankruptcy Code, 2016 ('Code'), and pursuant to provisions of SEBI (LODR) Regulations, 2015, please take notice that i, Anurag Kumar Sinha Reg No **IBBI/IPA-001/IP-P00427/2017-18/10750** Resolution Professional, submit Unaudited Financial Results of the Company for the Quarter ended 30th September 2022 as the firm of the independent auditor of the Company has not been peer reviewed and hence they have not provided Limited Review Report. Further, the financial results are signed by the Director of the Company.

This is for your information and record.

Thanking You,
Yours faithfully

Anurag Kumar Sinha
Resolution Professional of R.J. Biotech Limited
IBBI/IPA-001 /IP- P00427 / 2017-18/10750
Address- 3602, Redwood, Runwal Greens,
Mulund- Goregaon Link Road,
Bhandup (W), Mumbai-40007B



Audited Statement of Assets and Liabilities as on 30th Sep 2022		
Particulars	(Rs. in Lakhs)	
	As on 30-09-2022	As on 30-09-2021
I] EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	946.76	946.76
(b) Reserves & Surplus	(5,996.46)	(5,068.81)
(c) Money received against share warrants	-	-
Total Shareholders Fund	(5,049.70)	(4,122.05)
(2) Share Application money pending allotment		
(3) Deferred Government Grants		
(4) Minority Interest		
(5) Non-Current Liabilities		
(a) Long-term Borrowings	331.70	331.70
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long term Liabilities	58.85	58.60
(d) Long-term Provisions	-	-
Total Non-Current Liabilities	390.55	390.30
(6) Current Liabilities		
(a) Short-Term Borrowings	4,781.89	3,689.54
(b) Trade Payables	-	-
i) Micro enterprises and small enterprises	-	-
ii) Other than Micro enterprises and small enterprises	13.93	8.24
(c) Other Current Liabilities	19.25	238.08
(d) Short-Term Provisions	-	-
Total Current Liabilities	4,815.08	3,935.86
TOTAL	155.93	204.11
II] ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment	-	-
(i) Tangible Assets	140.06	154.82
(ii) Intangible Assets	-	-
(iii) Capital Work-in-progress	-	-
(iv) Intangible Assets under Development	-	-
Total Property, Plant and Equipment	140.06	154.82
(b) Non-Current Investments	-	-
(c) Deferred tax Assets (Net)	-	-
(d) Long-term loans & Advances	-	-
(e) Other non-Current assets	9.85	9.85
Total Non-Current Asset	149.91	164.66
(2) Current Assets		
(a) Current Investments	-	-
(b) Inventories	-	2.68
(c) Trade Receivables	-	33.32
(d) Cash & Cash equivalents	0.25	1.23
(e) Short-term loans and advances	-	1.74
(f) Other current assets	5.77	0.48
Total Current Asset	6.02	39.45
TOTAL	155.93	204.11
	-0.00	0.00
Note:		
01. The Un Audited financial results were reviewed		
02. There were no Investor Complaints received / pending as on 30/09/2022.		
03. The Company does not have more than one reportable primary segment in terms of Accounting Standard 17 (AS 17 - Segment Reporting) issued by ICAI/Company (Accounting Standards) Rules, 2006. Therefore, the Company is not required to submit separate segment wise report.		
04. Figures of the previous year have been re-grouped / re-arranged wherever considered necessary.		
For & on Behalf of the Board of Directors of R J BIO-TECH LIMITED  (Harshwardhan Joshi) Director DIN No.: 06742716		
Place: Aurangabad	Issued With approval Of Mr. Anurag Kumar Sinha Resolution Professional Of Rj Biotech Limited IBB/IPA-001/IP-P000424/2017-18/10750	
Date: 15/11/2022		

R J BIO-TECH LIMITED
CIN : L24234MH2005PLC158420
Statement of Audited Financial Results for the Half Year ended 30th Sept 2022

(Rs. in Lakhs)

Sr. No.	Particulars	Half Year Ended	Preceding Half year ended	Corresponding Half year ended	Year to date figure for current period ended	Year to date figures for the previous year ended	Previous year ended
		30.09.2022 Audited	31.03.2022 Audited	30.09.2021 Audited	30.09.2022 Audited	30.09.2021 Audited	31.03.2022 Audited
I	Revenue from Operations	-	-	1,167.42	-	1,167.42	1,389.68
II	Other Operating Income	60.80	(0.00)	26.97	60.80	26.97	67.39
III	Total Revenue (I+II)	60.80	(0.00)	1,194.39	60.80	1,194.39	1,457.07
IV	Expenditure						
a.	Cost of material consumed (Refer Note No. 2)	-	-	540.49	-	540.49	558.68
b.	Purchase of stock in trade	-	-	-	-	-	-
c.	Change in inventories of finished goods, work in progress and stock in trade (Refer Note No. 3)	-	97.62	(25.11)	-	(25.11)	97.62
d.	Employee benefit expenses	6.11	56.93	45.51	6.11	45.51	56.93
e.	Finance cost	0.01	0.00	0.12	0.01	0.12	581.62
f.	Depreciation and amortization expenses	-	-	4.90	-	4.90	6.71
g.	Other expenses - (Refer Note No. 4)	65.90	543.46	496.99	65.90	496.99	543.46
	Total Expenses IV	72.02	700.00	1,062.90	72.02	1,062.90	1,847.02
V	Profit/(loss) before Exceptional Items or tax (III - IV)	(11.21)	(389.95)	131.49	(11.22)	131.49	(389.95)
VI	Exceptional Items	(4.45)	(14.94)	(134.99)	4.45	(134.99)	(14.94)
VII	Profit/(loss) before tax (V-VI)	(15.67)	(404.90)	(3.50)	(15.67)	(3.50)	(404.89)
VIII	Tax Expenses	-	-	0.31	-	0.31	0.31
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	(15.67)	(404.90)	(3.81)	(15.67)	(3.81)	(405.20)
X	Profit/(loss) from discontinuing operations	-	-	-	-	-	-

XI	Prior Period Adjustments	-	510.89	-	-	-	510.89
XII	Profit/(loss) After Prior period adjustments	(15.67)	(915.79)	-	(15.67)	-	
XIII	Tax expense for discontinued operation	-	-	-	-	-	-
XIV.	Profit/(loss) from discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XV.	Profit/(loss) for the period (IX+XII)	(15.67)	(915.79)	(3.81)	(15.67)	(3.81)	(915.79)
XVI.	Other comprehensive income	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items	-	-	-	-	-	-
	B (i) that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Items that will be reclassified to profit or loss income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive Income for the period (XIII+XIV) (Comprising income for the period)	-	-	-	-	-	-
XVII.	Earnings per equity share (for continuing operation):						
	(1) Basic	(0.17)	(9.67)	(0.04)	(0.17)	(0.04)	(9.67)
XVIII.	(2) Diluted	-	-	-	-	-	-
	Earnings per equity share (for discontinued operation):						
XIX.	(1) Basic	(0.17)	(9.67)	(0.04)	(0.17)	(0.04)	(9.67)
	(2) Diluted	-	-	-	-	-	-
	Earnings per equity share (for discontinued and continuing operations)						
XX.	(1) Basic	(0.17)	(9.67)	(0.04)	(0.17)	(0.04)	(9.67)
	(2) Diluted	-	-	-	-	-	-

Place: Aurangabad
Date : 15.11.2022

For & on Behalf of the Board of Directors of
R J BIO-TECH LIMITED



Harshwardhan Joshi
Director
DIN No.: 06742716

Issued With approval Of Mr. Anurag Kumar Sinha

Resolution Professional Of Rj Biotech Limited

IBB/IPA-001/IP-P000424/2017-18/10750

R J BIO-TECH LIMITED
(CIN : L24234MH2005PLC158420)
Cash Flow Statement for the half year ended 30th Sept, 2022

Sr. No.	Particulars	As on 30.09.2022 (Actual)	As on 31.03.2021 (Audited)
A)	CASH INFLOW FROM OPERATING ACTIVITIES		
	Profit before tax	(15.67)	131.49
	Adjustments to reconcile profit before tax to cash provided by operating activities		
	Depreciation and Impairment	-	19.84
	Impairment Loss	-	-
	Interest & Finance Cost	0.01	0.12
	R & D Exp W/off	-	12.27
	Effects of Exceptional Items - Expired & Discarded Stock	-	(134.99)
	Deferred Expenses written off	-	-
	Operating Profit Before Working Capital Changes	(15.66)	28.73
	Adjusted for:		
	Changes in Inventories	-	123.28
	Changes in Trade Receivables	27.66	49.60
	Changes in Loans and advances and other assets	0.97	145.91
	Changes in Other Current Assets	(5.65)	0.97
	Changes in Liabilities & Provisions	(20.25)	(407.24)
	Change in Other non-current Assets	-	38.49
	Cash Generated From Operations	(12.93)	(20.26)
	Direct Tax Paid	-	(0.31)
	NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES	(12.93)	(20.57)
B)	CASH FLOWS FROM INVESTING ACTIVITIES		
0	Payment towards capital expenditure	-	-
	Sale of Property , Plant & Equipments	15.26	-
	Payment towards Research & Development & other deferred expenses	-	(12.27)
	Payment towards long-term loans and advances	(3.29)	-
	NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES	11.97	(12.27)
C)	CASH FLOWS FROM FINANCING ACTIVITIES		
	Repayment of Long Term Borrowings & Long Term Liabilities	-	(43.24)
	Changes in short-term borrowings	-	72.29
	Interest & Financial Charges	(0.01)	(0.12)
	NET CASH PROVIDED BY/(USED IN) FINANCING ACTIVITIES	(0.01)	28.93
	NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	(0.97)	(3.91)
	CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	1.22	5.13
	CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	0.25	1.23

Cash and cash equivalents is prepared on indirect basis and it consists of cash on hand and balances with banks.
This is the cashflow statement referred to in our report of even date.

For & on Behalf of the Board of Directors of
R J BIO-TECH LIMITED

Place: Aurangabad
Date : 15.11.2022


(Harshwardhan Joshi)
Director
DIN No.: 06742716

Issued With approval Of Mr. Anurag Kumar Sinha
Resolution Professional Of Rj Biotech Limited
IBB/PA-001/IP-P000424/2017-18/10750